<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893203</url>
  </required_header>
  <id_info>
    <org_study_id>R13073 / Q257</org_study_id>
    <secondary_id>2013-002108-15</secondary_id>
    <nct_id>NCT01893203</nct_id>
  </id_info>
  <brief_title>Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)</brief_title>
  <acronym>2013-002108-15</acronym>
  <official_title>Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joint Authority for Päijät-Häme Social and Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Joint Authority for Päijät-Häme Social and Health Care</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the efficacy of two photosensitizers,
      methyl-aminolaevulinate (MAL) and 5-aminolaevulinic nanoemulsion (BF-200 ALA) in the
      treatment of facial actinic keratosis. We use randomized, double-blinded prospective study
      design. The efficacy will be assessed clinically, histopathologically and
      immunohistochemically.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actinic keratoses (AKs) are superficial premalignant skin lesions that can progress into an
      invasive or metastatic squamous cell carcinoma. AKs can be treated with photodynamic therapy
      (PDT), of which cure rate compares to cryo surgery with an excellent cosmesis. In PDT the AK
      lesions are first curettaged, then a photosensitizer is applied on the skin and let to absorb
      for 3 hours. The skin is illuminated using a blue or red light source light source depending
      on the photosensitizer, which induces activation of protoporphyrin IX (PpIX) and phototoxic
      reaction destroying the cancer cells.

      The approved photosensitizers in Europe are methyl-aminolevulinic acid cream, (MAL, Metvix™,
      Galderma), a patch containing 5-aminolevulinic acid (5-ALA, Alacare®, Spirig AG) and
      5-aminolevulinic acid gel (BF-200 ALA, Ameluz®, Biofrontera AG) to be used with a red LED
      light (630-635 nm). In North America a 5-aminolevulinic acid stick (5-ALA, Levulan®
      Kerastick) can also be used with a blue light source (417 nm).

      PpIX absorption peaks are within the visual spectrum of light, which allows PpIX daylight
      activation. During natural daylight PDT (NDL-PDT) protocol, PpIX is continuously activated
      during its development, whereas in conventional PDT (LED-PDT) using red LED lamps, large
      amounts of accumulated PpIX are momentarily activated.

      Since skin field cancerization refers to presence of different degrees of visible and
      invisible dysplastic changes, the whole area should be treated to prevent the development of
      non-melanoma skin cancers (NMSCs). NDL-PDT enables treatment of field cancerization in one
      sitting whereas LED-PDT may need repeated illuminations to cover the whole area. NDL-PDT
      results in enhanced cost-efficacy due to reduced staff expenses, since there's no need for
      sensitizer absorption and illumination.

      At the moment two photosensitizers have marketing authorization in Finland, ALA (Ameluz®) and
      MAL (Metvix™). We are piloting a study comparing the efficacy of these two light sensitizers
      in NDL-PDT. The efficacy of the treatments will be assessed clinically, histopathologically
      and immunohistochemically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological Lesion Clearance</measure>
    <time_frame>0 (baseline) and 3 months</time_frame>
    <description>Punch biopsies were taken symmetrically on both treatment fields from equally graded &gt;6 mm AKs prior to treatment and again at 3 months, blinded observer (pathologist). HE- and p53-stainings. Samples not fulfilling the criteria of an AK were defined as healthy or completely cleared. The p53 reactivity expressed as average percentage of positive nuclei in three consecutive high power fields from the region of highest reactivity (&lt;10 % normal)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12 hours</time_frame>
    <description>Pain using visual analog scale (VAS 0-10, where 0 is no pain and 10 is the worst pain imaginable) on both treatment sides is assessed in every 30 minutes during 2-hour sun-exposure and afterwards once in two hours until 9 p.m.
(treatment day). Of these values, the mean maximal pain is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Lesion Clearance</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical lesion clearance is observed by a blinded observer</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Reactions</measure>
    <time_frame>1 week</time_frame>
    <description>Adverse reactions are evaluated by blinded observer at one week after treatment. A dermatologist will assess which side of the face or scalp presents a stronger reaction.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Multiple Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>BF-200 ALA vs MAL</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF-200 ALA cream</intervention_name>
    <description>The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.</description>
    <arm_group_label>BF-200 ALA vs MAL</arm_group_label>
    <other_name>5-aminolaevulenic acid nanoemulsion</other_name>
    <other_name>Ameluz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAL cream</intervention_name>
    <description>The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.</description>
    <arm_group_label>BF-200 ALA vs MAL</arm_group_label>
    <other_name>methylaminolevulinic acid</other_name>
    <other_name>Metvix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  actinic keratoses symmetrically on face or scalp

          -  age over 18 years

          -  there must be at minumum one ak sized 6mm2 symmetrically on both sides

          -  patients must be able to make the decision to attend independently

        Exclusion Criteria:

          -  pregnancy

          -  lactation

          -  lack of compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noora E Neittaanmäki-Perttu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toni T Karppinen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Päijänne Tavastia Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taneli Tani, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Päijänne Tavastia Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2013</study_first_posted>
  <results_first_submitted>December 23, 2015</results_first_submitted>
  <results_first_submitted_qc>May 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>May 29, 2016</last_update_submitted>
  <last_update_submitted_qc>May 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
    <mesh_term>Photosensitizing Agents</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>25109244</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BF200 ALA vs MAL</title>
          <description>5-aminulevulinic acid nanoemulsion (BF-200 ALA, Ameluz, Biofrontera) and methylaminolevulinic acid (MAL, Metvix, Galderma) in randomized split face design on symmetrical treatment areas.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>14 patients were recruited. One withdrew because of conditions not related to the study. This patient was not included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>BF-200 ALA vs MAL</title>
          <description>BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.8" lower_limit="66" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of AKs</title>
          <units>Number of actinic keratoses (AKs)</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Histological Lesion Clearance</title>
        <description>Punch biopsies were taken symmetrically on both treatment fields from equally graded &gt;6 mm AKs prior to treatment and again at 3 months, blinded observer (pathologist). HE- and p53-stainings. Samples not fulfilling the criteria of an AK were defined as healthy or completely cleared. The p53 reactivity expressed as average percentage of positive nuclei in three consecutive high power fields from the region of highest reactivity (&lt;10 % normal)</description>
        <time_frame>0 (baseline) and 3 months</time_frame>
        <population>Punch biopsies bilaterally on treatment fields</population>
        <group_list>
          <group group_id="O1">
            <title>BF200 ALA vs MAL</title>
            <description>BF-200 ALA (Ameluz, Biofrontera) and MAL (Metvix, Galderma) in randomized split face design on symmetrical treatment areas.</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Lesion Clearance</title>
          <description>Punch biopsies were taken symmetrically on both treatment fields from equally graded &gt;6 mm AKs prior to treatment and again at 3 months, blinded observer (pathologist). HE- and p53-stainings. Samples not fulfilling the criteria of an AK were defined as healthy or completely cleared. The p53 reactivity expressed as average percentage of positive nuclei in three consecutive high power fields from the region of highest reactivity (&lt;10 % normal)</description>
          <population>Punch biopsies bilaterally on treatment fields</population>
          <units>percentage of complete clearance</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BF-200 ALA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.375</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Pain using visual analog scale (VAS 0-10, where 0 is no pain and 10 is the worst pain imaginable) on both treatment sides is assessed in every 30 minutes during 2-hour sun-exposure and afterwards once in two hours until 9 p.m.
(treatment day). Of these values, the mean maximal pain is assessed.</description>
        <time_frame>12 hours</time_frame>
        <population>Patients</population>
        <group_list>
          <group group_id="O1">
            <title>BF200 ALA vs MAL</title>
            <description>BF-200 ALA (Ameluz, Biofrontera) and MAL (Metvix, Galderma) in randomized split face design on symmetrical treatment areas.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Pain using visual analog scale (VAS 0-10, where 0 is no pain and 10 is the worst pain imaginable) on both treatment sides is assessed in every 30 minutes during 2-hour sun-exposure and afterwards once in two hours until 9 p.m.
(treatment day). Of these values, the mean maximal pain is assessed.</description>
          <population>Patients</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BF-200 ALA treatment sides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.4" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAL treatment sides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Lesion Clearance</title>
        <description>Clinical lesion clearance is observed by a blinded observer</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BF200 ALA vs MAL</title>
            <description>BF-200 ALA (Ameluz, Biofrontera) and MAL (Metvix, Galderma) in randomized split face design on symmetrical treatment areas.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Lesion Clearance</title>
          <description>Clinical lesion clearance is observed by a blinded observer</description>
          <units>percentage of complete clearance</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>AKs total</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BF-200 ALA treated lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="75.2" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAL treated lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" lower_limit="64.4" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Reactions</title>
        <description>Adverse reactions are evaluated by blinded observer at one week after treatment. A dermatologist will assess which side of the face or scalp presents a stronger reaction.</description>
        <time_frame>1 week</time_frame>
        <population>One week after the first photodynamic therapy (PDT), seven patients had more severe reactions (erythema, crusting) at the site treated with BF-200 ALA, five patients had more severe reactions at the MAL site and one patient showed no difference between sites.</population>
        <group_list>
          <group group_id="O1">
            <title>BF200 ALA vs MAL</title>
            <description>BF-200 ALA (Ameluz, Biofrontera) and MAL (Metvix, Galderma) in randomized split face design on symmetrical treatment areas.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Reactions</title>
          <description>Adverse reactions are evaluated by blinded observer at one week after treatment. A dermatologist will assess which side of the face or scalp presents a stronger reaction.</description>
          <population>One week after the first photodynamic therapy (PDT), seven patients had more severe reactions (erythema, crusting) at the site treated with BF-200 ALA, five patients had more severe reactions at the MAL site and one patient showed no difference between sites.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BF-200 ALA treated areas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAL treated areas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No difference between the sides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BF200 ALA vs MAL</title>
          <description>BF-200 ALA (Ameluz, Biofrontera) and MAL (Metvix, Galderma) in randomized slipt face design on symmetrical treatment areas.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reactions: erythema, crusting, scaling</sub_title>
                <description>Erythema, crusting and scaling were assessed all together as one score of mild, moderate or severe</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain in VAS scale 1-10</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Noora Neittaanmäki-Perttu</name_or_title>
      <organization>Helsinki university hospital</organization>
      <phone>+358407190362</phone>
      <email>noora.neittaanmaki@fimnet.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

